Sana Biotechnology, Inc. (NASDAQ: SANA) has recently appointed Brian Piper as its new Executive Vice President and Chief Financial Officer. Piper, who brings with him over 25 years of experience in the biopharmaceutical industry, has held various financial and operational positions in companies such as Scorpion Therapeutics, Antares Therapeutics, Prelude Therapeutics, Aevi Genomic Medicine, and Shire Pharmaceuticals.
Sana Biotechnology is anticipating generating initial clinical data for SC451 in the treatment of type 1 diabetes and SG293 in a B-cell related disease over the next 12-18 months. The company is also experiencing significant momentum in its type 1 diabetes and in vivo CAR-T programs.
Piper's appointment comes at a crucial time for Sana as the company aims to advance its portfolio, optimize long-term value creation, and deliver transformative therapies for patients. His expertise in capital formation and disciplined capital allocation is expected to contribute to the company's financial and operational excellence.
Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients, with operations in Seattle, WA, Cambridge, MA, and South San Francisco, CA. Following these announcements, the company's shares moved -1.93%, and are now trading at a price of $4.58. Check out the company's full 8-K submission here.
